试点研究Pitolisant,一个基因素-3逆agonist,作为对耐火不安腿综合征的辅助治疗
1Stanley H. Appel Department of Neurology, Houston Methodist Hospital, Houston, TX, USA; Weill Cornell Medical School, Dept of Neurology, USA.
Sleep medicine
|June 24, 2025
概括
皮托利桑 (Pitolisant) 是一种针对不安腿综合征 (RLS) 的新疗法,在RLS症状尺度上显著改善. 这项研究表明,皮托利桑可能有助于白天的RLS后果,这需要进一步调查.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 不安腿综合征 (RLS) 往往对现有的治疗方法如铁,多巴胺激素, gabapentinoids 和阿片类药物变得耐药.
- 镇静性抗组胺剂可以悖论地恶化RLS症状.
- 皮托利桑 (Pitolisant) 是一种组胺-3抗剂,增加了中枢神经系统的组胺传输,并被批准用于麻醉症.
研究的目的:
- 评估皮托利桑特在治疗不充分的不安腿综合征患者中的疗效和耐受性.
- 评估皮托利桑对核心RLS症状和白天后果的影响.
主要方法:
- 一项开放性试验,涉及21名RLS患者,至少使用另一种RLS药物治疗不充分的RLS患者.
- 皮托利桑剂的剂量每天升至35.6毫克,主要疗效通过国际RLS评级尺度 (IRLSRS) 测量8周后.
- 二级终点包括对疲劳,嗜睡,认知和睡眠质量的评估.
主要成果:
- 国际RLS评级表 (IRLSRS) 在8周后从24.5显著改善到17.2 (p < 0.001).
- 在RLS-6和爱普沃思睡眠量表得分上也注意到了显著的改善.
- 疲劳,认知和抑郁等级保持不变. 失眠是最常见的不良事件,在9名经历AE的受试者中,有6人报告了不良事件.
结论:
- 皮托利桑 (Pitolisant) 一般耐受良好,并且在改善RLS症状尺度方面表现出有效性.
- 这些发现表明,皮托利桑在缓解RLS白天后果方面可能比核心症状更有效.
- 有控制的试验是有必要的,以进一步验证这些发现.
相关概念视频
Restless Leg Syndrome and Night Terrors
259
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
259
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260
Drugs for Treatment of Constipation-Predominant IBS
353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353


